Neurology & Psychiatry · LP-159
Diazepam Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-159Neurology & Psychiatry
- Generic identity
- DiazepamTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-159
- Generic ingredient
- Diazepam
- Dosage form
- Tablet
- Proposed strength
- 2 mg; 5 mg; 10 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
About Diazepam
Diazepam is a benzodiazepine that enhances inhibitory signalling in the nervous system. Oral tablets have defined clinical roles that can include selected anxiety, muscle-spasm, withdrawal or seizure-related circumstances under professional direction. The medicine can impair alertness and has dependence potential. An oral catalogue entry should not be interpreted as an invitation to self-select treatment or a description of an injectable emergency protocol.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
The clinical purpose and intended duration require clear review, including alternative approaches and the risks of other sedating medicines. Continued use can lead to physical dependence even when taken as prescribed. Alcohol-withdrawal and seizure care need appropriate clinical pathways and cannot be reduced to a tablet choice. Legal classification and prescription controls vary by destination and must be established separately from this educational ingredient description.
Important safety considerations
Sedation, impaired coordination, falls and memory effects can occur. Combining diazepam with opioids, alcohol or other central nervous system depressants can cause profound respiratory depression, coma or death. Dependence and withdrawal are important risks; abrupt stopping after regular use can produce serious reactions, including seizures. Respiratory disease, sleep apnoea, liver impairment and older age require particular assessment. Severe drowsiness or slowed breathing needs emergency help.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue lists oral tablets in several strengths. These are not substitutes for injection, rectal or nasal rescue formulations. Exact tablet characteristics, packaging and any destination-specific controlled-medicine requirements require verified documentation.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review the clinical indication, sedation burden, respiratory and liver status, dependence risk and a supervised review or discontinuation plan. Confirm legal supply requirements and authorized labeling.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Diazepam
- Dosage form / presentation
- Tablet
- Catalogue strength
- 2 mg; 5 mg; 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- The oral tablet record does not establish controlled-drug permissions for any destination, nor does catalogue inclusion authorise distribution.
- Tablet formulation, scoring and substitution with injectable, rectal, nasal or other diazepam presentations are not established.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Diazepamgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-159, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-159.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.